Location History:
- Mount Kisco, NY (US) (2018)
- Pleasantville, NY (US) (2023)
Company Filing History:
Years Active: 2018-2025
Title: Innovations of Matthew Koss in Tauopathy Research
Introduction
Matthew Koss is an accomplished inventor based in Mount Kisco, NY (US). He has made significant contributions to the field of genetic research, particularly in the study of tauopathies. With a total of 8 patents to his name, Koss is recognized for his innovative approaches to understanding and treating neurodegenerative diseases.
Latest Patents
Koss's latest patents include a CRISPR/Cas screening platform designed to identify genetic modifiers of tau seeding or aggregation. This includes the development of Cas-protein-ready tau biosensor cells and CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells. These inventions provide methods for screening genetic modifiers of tau seeding or aggregation. Additionally, Koss has developed reagents and methods for sensitizing these cells to tau seeding activity or tau aggregation. His research has identified models of tauopathy, including BANF1, PPP2CA, and ANKLE2, as genes that promote tau aggregation when disrupted. Improved tauopathy models, such as cells, tissues, or animals with mutations in or inhibition of expression of these genes, have also been provided. Koss's work includes methods for using these improved models to assess therapeutic candidates for tauopathy treatment.
Career Highlights
Matthew Koss is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in genetic modifiers and tauopathies. His innovative work has positioned him as a key figure in the field of neurodegenerative disease research.
Collaborations
Koss collaborates with notable colleagues, including Marine Prissette and Brian Zambrowicz, to further enhance the impact of his research.
Conclusion
Matthew Koss's contributions to the field of tauopathy research through his innovative patents and collaborations highlight his role as a leading inventor in genetic research. His work continues to pave the way for advancements in understanding and treating neurodegenerative diseases.